Company Profile
Sonoma Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Sonoma Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Sonoma Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Sonoma Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Sonoma Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
SNOA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Sonoma’s catalysts are wound-care and skin-health product demand, along with any update that clarifies the commercial path. The business moves on product adoption.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
Source: Sonoma Pharmaceuticals
- 02
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
Source: Sonoma Pharmaceuticals
- 03
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando
Source: Sonoma Pharmaceuticals
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.